Bajaj Healthcare Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. PE: 19.4. ROE: 10.7%. This stock is not currently in the Nifty 500 momentum outperformers list.
Deep value thesis based on recent earnings • Updated Feb 22, 2026
Export-led API business transformation driving margin recovery with CNS drug pipeline providing optionality
Verdict
TURNAROUND_IN_PROGRESS
Re-rating catalysts over the next 2-4 quarters • Updated Feb 22, 2026
Magnesium L-Threonate launch gaining traction in cognitive health segment
Impact: +₹50 Cr revenue
“Successful launch in Q3 FY26 with initial market response”
CNS drug trial completion expected to unlock regulatory approvals
Impact: +₹200 Cr revenue
“CDSCO approval for Phase III trials received in Q3 FY26”
Higher-margin export business becoming dominant revenue stream
“API exports grew 109.8% YoY, currently at ~45% of total revenue”
Risks that could prevent re-rating or deepen the value trap
Domestic API prices drop 20%+ due to competition
Impact: -300 bps margin impact
Management view: Diversification into exports reducing domestic dependency
Monitor: Domestic API revenue growth rate
Suvorexant trial results delayed beyond Q1 FY27
Impact: -150 bps margin impact
Management view: Multiple pipeline drugs reducing single-point failure risk
Monitor: Number of active clinical trials
Forward-looking targets from management for FY27
Revenue Growth Target
25%
Implied PAT Growth
30%
OPM Guidance
21%
Capex Plan
₹150 Cr
Credit Growth Target
0%
NIM Guidance
0%
Key Milestones
• Cenobamate trial results
• Magtein revenue ramp
The above analysis is AI-generated from publicly available financial data. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Bajaj Healthcare Ltd's latest quarterly results (Dec 2025) show
Bajaj Healthcare Ltd's current PE ratio is 19.4x.
Bajaj Healthcare Ltd's price-to-book ratio is 1.9x.
Bajaj Healthcare Ltd's fundamental strength based on key financial ratios
Bajaj Healthcare Ltd has a debt-to-equity ratio of N/A.
Bajaj Healthcare Ltd's return ratios over recent years
Bajaj Healthcare Ltd's operating cash flow is positive (FY2025).
Bajaj Healthcare Ltd's current dividend yield is 0.33%.
Bajaj Healthcare Ltd's shareholding pattern (Mar 2026)
Bajaj Healthcare Ltd's promoter holding has decreased recently.
Bajaj Healthcare Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Bajaj Healthcare Ltd has 3 key growth catalysts identified from recent earnings analysis
Bajaj Healthcare Ltd has 2 key risks worth monitoring
Bajaj Healthcare Ltd's management has provided the following forward guidance for FY27
Based on quantitative research signals, here is why Bajaj Healthcare Ltd may be worth studying
Bajaj Healthcare Ltd investment thesis summary:
Bajaj Healthcare Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
